|2022-08-30||HC Wainwright & Co.||Downgrade||Buy||Neutral|
|2022-03-28||HC Wainwright & Co.||Upgrade||Buy|
|2021-11-29||HC Wainwright & Co.||Upgrade||Buy|
|2022-12-30||Sofinnova Investments, Inc.||4.75M||483.51K||4.37%|
|2022-12-30||NEA Management Company, LLC||4.59M||466.91K||4.22%|
|2022-12-30||Credit Suisse Ag/||1.75M||178.21K||1.61%|
|2022-12-30||Zurcher Kantonalbank (Zurich Cantonalbank)||668.49K||68.05K||0.62%|
|2022-12-30||Pictet Asset Management SA||363.77K||37.03K||0.33%|
|2022-12-30||Cutter & Co. Brokerage, Inc.||201.20K||20.48K||0.19%|
|2022-11-29||Fidelity NASDAQ Composite Index Fund||82.23K||8.37K||0.08%|
ObSeva Announces Positive Pilot Study Results From Linzagolix In Adenomyosis
Obseva SA (NASDAQ: OBSV) announced the publication in the journal Fertility and Sterility of a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. The study showed the patient treated with linzagolix saw alleviation of symptoms such as cessation of bleeding, improvement in pelvic pain, resolution of anemia and shrinkage of uterus at week 12.
The symptoms continued to improve with the subsequent 12 weeks of treatment, and the effect lingered at eight weeks following the treatment.
Pending confirmation of the results in additional patients, ObsEva said it may pursue additional studies to support supplemental labeling for the treatment of adenomyosis in reproductive-age women.
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.